PRINCETON, N.J., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that three posters highlighting its development program for Pompe disease will be included at the 29th Annual Congress of the World Muscle Society being held October 8-12, 2024 in Prague, Czechia.

Poster Session: Pompe Disease

Abstract Title: Cipaglucosidase alfa + miglustat in late-onset Pompe disease: two non-ambulatory patients switching from high-dose, high-frequency alglucosidase alfa (Poster #657P)

• Presenter: Barry J. Byrne, MD, PhD, University of Florida, Gainesville, FL, U.S.A.
• Poster Session: Friday, October 11, 3:45 – 4:45 p.m. CET
• Location: Forum Hall, The Prague Congress Centre

Abstract Title: Post-baseline outcomes of the UK Early Access to Medicines Scheme registry for cipaglucosidase alfa plus miglustat in late-onset Pompe disease (Poster #670P)

• Presenter: Mark Roberts, MD, Salford Royal NHS Foundation Trust, Greater Manchester Neurosciences Centre, Manchester, U.K.
• Poster Session: Friday, October 11, 3:45 – 4:45 p.m. CET
• Location: Forum Hall, The Prague Congress Centre

Abstract Title: Miglustat: a first-in-class enzyme stabilizer for late-onset Pompe disease (Poster #671P)

• Presenter: Tahseen Mozaffar, MD, Department of Neurology, University of California, Irvine, CA, U.S.A.
• Poster Session: Friday, October 11, 3:45 – 4:45 p.m. CET
• Location: Forum Hall, The Prague Congress Centre

For more information on the WMS 2024 Annual Congress, please visit www.wms2024.com

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn.

CONTACTS:

Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
(609) 662-3809

Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
(609) 662-5079